FGF21 and obesity disorder: These findings suggest that the treatment with alogliptin has no effects on obesity, hyperglycemia, and plasma Fgf21 levels in individually housed KKAy mice, whereas the treatment with liraglutide reduces the obesity and hyperglycemia independently of plasma active GLP-1 levels.